Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo

@article{Yamazaki2011NovelAD,
  title={Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo},
  author={Ryuta Yamazaki and Yukiko Nishiyama and Tomio Furuta and Hiroshi Hatano and Yoshiaki Igarashi and Naoyuki Asakawa and Hiroshi Kodaira and Hiroyuki Takahashi and Ritsuo Aiyama and Takeshi Matsuzaki and Naomi Yagi and Yoshikazu Sugimoto},
  journal={Molecular Cancer Therapeutics},
  year={2011},
  volume={10},
  pages={1252 - 1263}
}
Breast cancer resistance protein (BCRP/ABCG2) confers resistance to anticancer drugs such as 7-ethyl-10-hydroxycamptothecin (SN-38, an active metabolite of irinotecan), mitoxantrone, and topotecan. In this study, we examined the reversing effects of YHO-13177, a novel acrylonitrile derivative, and its water-soluble diethylaminoacetate prodrug YHO-13351 on the BCRP-mediated drug resistance. YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human… 

Figures from this paper

ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
TLDR
Combination therapy with irinotecan and YHO-13351 would not only accelerate the antitumor effect of this regimen, but also play a crucial role in preventing resistance or relapse.
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts
TLDR
Safety and other pharmacological data strongly support the reglementary preclinical development of MBL-II-141, a specific and potent ABCG2 inhibitor that would be a valuable agent to improve drug distribution into the brain to efficiently treat aggressive gliomas.
Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
TLDR
Treatment of both S120 sublines with known ABCG2 inhibitors restored toxicity of SN-38, and the combination of YHO-13351 with IMMU-132 increased the median survival of mice bearing NCI-N87-S120 xenografts, providing a rationale for combination therapy of IM MU-132 and inhibitors of ABC transporters.
A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo
TLDR
It is found that the phenylfurocoumarin derivative (R)-9-(3,4-dimethoxyphenyl)-4-((3,3-dimethyloxiran-2-yl)methoxy)-7H-furo [3,2-g]chromen-7-one (PFC) has promise as a therapeutic to overcome ABCG2-mediated MDR, to improve the efficiency of cancer chemotherapy.
Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts
TLDR
Three compounds hypothesized that three compounds, which represent a new piperazine-substituted pyrazolo[1,5]pyrimidine substructure class of ABCG2-specific antagonists, would restore chemosensitivity to drug-resistant ovarian cancer in vitro and in vivo, were combined to address the treatment difficulties associated with chemotherapeutic resistance.
New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells
TLDR
Kinase profiling of cancer relevant protein kinases identified the two 3-aryl-2-(thien-2-yl)acrylonitrile derivatives 1b and 1c as (multi-)kinase inhibitors with a preferential activity against the VEGFR-2 tyrosine kinase.
ABCG2/BCRP: Specific and Nonspecific Modulators
TLDR
The aim of the present review is to describe and highlight specific and nonspecific modulators of ABCG2 reported to date based on the selectivity of the compounds, as many of them are effective against one or more ABC transport proteins.
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
...
1
2
3
4
...

References

SHOWING 1-10 OF 57 REFERENCES
Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance
TLDR
This study shows that phytoestrogens/flavonoids, such as genistein, naringenin, acacetin, and kaempferol, potentiated the cytotoxicity of SN-38 and mitoxantrone in BCRP-transduced K562 (K562/BCRP) cells and suggests that flavonoid and glycosylated flavonoids may be useful in overcoming B CRP-mediated drug resistance in tumor cells.
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
TLDR
GF120918 effectively competes with [3H]azidopine for binding P-glycoprotein, pointing to this transport membrane protein as its likely site of action and does not modify significantly the distribution or the elimination of doxorubicin in mice ruling out the possibility that the antitumor effects seen might be explained by pharmacokinetic interactions.
Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic
TLDR
It is suggested that novobiocin effectively overcomes BCRP‐mediated drug resistance at acceptable concentrations.
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
TLDR
It is suggested that fumitremorgin C is a highly selective chemosensitizing agent for the resistance pathway the authors have identified and can be used as a specific pharmacological probe to distinguish between the diverse resistance mechanisms that occur in the MDR cell.
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
TLDR
A new tetracyclic analogue of FTC, Ko143, is evaluated as a practical inhibitor of BCRP, proving highly active for increasing the intracellular drug accumulation and reversing Bcrp1/BCRP-mediated multidrug resistance.
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
TLDR
It is concluded that colon and breast cancer cells have a capacity for glucuronidation that could contribute to intrinsic drug resistance in colon cancer cells and may be acquired in breast cancers cells.
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
TLDR
Gefitinib inhibits the transporter function of BCRP and reverses B CRP-mediated drug resistance both in vitro and in vivo, and suggests that gefit inib may overcome BCRp- mediated drug resistance by inhibiting the pump function ofBCRP.
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
TLDR
Bcrp1 mediates apically directed drug transport, appears to reduce drug bioavailability, and protects fetuses against drugs, and it is proposed that strategic application of BCRP inhibitors may lead to more effective oral chemotherapy with topotecan or other B CRP substrate drugs.
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
TLDR
This work provides the first evidence that imatinib is a substrate for BCRP, that it competes with mitoxantrone for drug export, and that B CRP-mediated efflux can be reversed by the fumitremorgin C analog Ko-143.
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
TLDR
Among commercially available estrogen antagonists and agonists tested, diethylstilbestrol showed the strongest BCRP-reversing activity, suggesting that estrone and tamoxifen derivatives interact with the same drug-binding site of B CRP.
...
1
2
3
4
5
...